Ratings Naturhouse Health, S.A.

Equities

NTH

ES0105043006

Market Closed - BME 11:35:26 2024-04-26 EDT 5-day change 1st Jan Change
1.64 EUR -1.80% Intraday chart for Naturhouse Health, S.A. -0.61% +1.23%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 9.65 for the current year.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For several months, analysts have been revising their EPS estimates roughly upwards.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • Most analysts recommend that the stock should be sold or reduced.

Ratings chart - Surperformance

Sector: Other Specialty Retailers

1st Jan change Capi. Investor Rating ESG Refinitiv
+1.23% 105M -
+27.38% 29.56B
A-
+4.90% 5.71B
B-
-11.42% 4.42B
C
+14.25% 4.17B
C+
+4.23% 1.85B -
B-
-4.59% 1.77B
C+
-13.78% 1.26B -
C
-17.17% 1.15B
B-
-2.08% 613M
B
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NTH Stock
  4. Ratings Naturhouse Health, S.A.